These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1542 related articles for article (PubMed ID: 12014897)

  • 1. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
    Krcmery V; Barnes AJ
    J Hosp Infect; 2002 Apr; 50(4):243-60. PubMed ID: 12014897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital.
    Muñoz P; Sánchez-Somolinos M; Alcalá L; Rodríguez-Créixems M; Peláez T; Bouza E
    J Antimicrob Chemother; 2005 Feb; 55(2):188-93. PubMed ID: 15650001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management.
    Chen SC; Marriott D; Playford EG; Nguyen Q; Ellis D; Meyer W; Sorrell TC; Slavin M;
    Clin Microbiol Infect; 2009 Jul; 15(7):662-9. PubMed ID: 19614718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo pathogenicity of eight medically relevant Candida species in an animal model.
    Arendrup M; Horn T; Frimodt-Møller N
    Infection; 2002 Oct; 30(5):286-91. PubMed ID: 12382088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neonatal Candida infections and the antifungal susceptibilities of the related Candida species].
    Altuncu E; Bilgen H; Cerikçioğlu N; Ilki A; Ulger N; Bakır M; Akman I; Ozek E
    Mikrobiyol Bul; 2010 Oct; 44(4):593-603. PubMed ID: 21063972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Investigation of antifungal susceptibilities and some virulence factors of Candida strains isolated from blood cultures and genotyping by RAPD-PCR].
    Gültekin B; Eyigör M; Tiryaki Y; Kırdar S; Aydın N
    Mikrobiyol Bul; 2011 Apr; 45(2):306-17. PubMed ID: 21644074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of broth microdilution and E-test methods for the antifungal susceptibility testing of Candida spp. strains isolated from blood cultures].
    Ozcan SK; Mutlu B; Dündar D; Willke A
    Mikrobiyol Bul; 2010 Apr; 44(2):263-71. PubMed ID: 20549961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antifungal susceptibility of Candida spp. isolates from blood cultures in a five-year period (1997-2001)].
    Durán MT; Velasco D; Canle D; Moure R; Villanueva R
    Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):488-92. PubMed ID: 14572381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent experience with fungaemia: change in species distribution and azole resistance.
    Chakrabarti A; Chatterjee SS; Rao KL; Zameer MM; Shivaprakash MR; Singhi S; Singh R; Varma SC
    Scand J Infect Dis; 2009; 41(4):275-84. PubMed ID: 19229762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candida albicans versus non-albicans bloodstream infection in patients in a tertiary hospital: an analysis of microbiological data.
    Samonis G; Kofteridis DP; Saloustros E; Giannopoulou KP; Ntziora F; Christidou A; Maraki S; Falagas ME
    Scand J Infect Dis; 2008; 40(5):414-9. PubMed ID: 18418802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
    Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
    Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Candida species in different hospital wards and their susceptibility to antifungal agents: results of a three year survey.
    Fadda ME; Podda GS; Pisano MB; Deplano M; Cosentino S
    J Prev Med Hyg; 2008 Jun; 49(2):69-74. PubMed ID: 18847180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biofilm production and antifungal susceptibility patterns of Candida species].
    Yücesoy M; Karaman M
    Mikrobiyol Bul; 2004; 38(1-2):91-8. PubMed ID: 15293907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presumptive identification of Candida species other than C. albicans, C. krusei, and C. tropicalis with the chromogenic medium CHROMagar Candida.
    Hospenthal DR; Beckius ML; Floyd KL; Horvath LL; Murray CK
    Ann Clin Microbiol Antimicrob; 2006 Jan; 5():1. PubMed ID: 16390552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation.
    Gottfredsson M; Vredenburgh JJ; Xu J; Schell WA; Perfect JR
    Cancer; 2003 Jul; 98(1):24-30. PubMed ID: 12833451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey.
    Pemán J; Cantón E; Quindós G; Eraso E; Alcoba J; Guinea J; Merino P; Ruiz-Pérez-de-Pipaon MT; Pérez-del-Molino L; Linares-Sicilia MJ; Marco F; García J; Roselló EM; Gómez-G-de-la-Pedrosa E; Borrell N; Porras A; Yagüe G;
    J Antimicrob Chemother; 2012 May; 67(5):1181-7. PubMed ID: 22351683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
    Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
    Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.